Corcept’s stock up as relacorilant meets OS goal in Phase III ovarian cancer trial
Corcept recently suffered a blow after relacorilant was rejected by the FDA for use in Cushing’s syndrome.
Corcept recently suffered a blow after relacorilant was rejected by the FDA for use in Cushing’s syndrome.
91% of clinical research associates concerned with burnout and turnover, third-party data query resolution can cost sponsors millions.
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Patient-centric approaches thrive on wearables and remote access in trials
Pharma’s AI prospects get nudged into the future with EU’s AI act
Are regulators keeping pace with AI adoption in clinical trials?
AI-automated IVF procedures represent a new era in fertility treatment